Details for Patent: 5,248,699

Scope and Claim Strength of US Patent 5,248,699: crystalline hydrochloride polymorph and therapeutic use claims

US Patent 5,248,699 is directed to a specific hydrochloride crystalline polymorph of a single, fully defined chiral tetrahydro-naphthylamine API, with claims anchored to objective solid-state identifiers (XRPD peak set; FTIR band set in KBr) and, in dependent claims, single-crystal X-ray structural parameters and atomic-coordinate tables. The estate then broadens into downstream pharmaceutical composition and method-of-treatment claims covering multiple therapeutic indications under a single administration paradigm.

What does US Patent 5,248,699 claim exactly: crystalline hydrochloride polymorph scope by XRPD and FTIR?

Core inventive concept. The patent claims a crystalline polymorph of the hydrochloride salt of (1S-cis)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-naphthalenamine, with the polymorph defined by:

• XRPD signature: characteristic 2θ peaks at approximately 7.1, 12.7, 14.1, 15.3, 15.7, 21.2, 23.4, 26.3 degrees 2θ (Claim 1).
• FTIR in KBr signature: a characteristic band set with enumerated ranges and point values (Claim 2), and then restated in Claim 3.

How tight is the XRPD peak-set definition in Claim 1?

Claim 1 does not claim “any polymorph with similar peaks.” It claims polymorphs exhibiting an XRPD pattern having characteristic peaks at the listed approximate locations. Practically, that converts the claim to a metrology gate: infringement turns on whether the accused solid-state form reproduces the specified peak positions within the “approximately” tolerance recognized under claim construction.

Key scope implications:

• Different polymorphs that shift peak positions outside accepted tolerance may fall outside the claim.
• Salt identity is fixed: the API must be the hydrochloride salt.
• Stereochemical identity is fixed: (1S-cis) is required.

What is the FTIR-defined band scope in Claim 2?

Claim 2 ties the polymorph to an FTIR spectrum in KBr with bands/ranges including:

• 3100–3000 (w)
• 3000–2800 (m); 2710–2500 (m)
• 2500–2450 (m)
• 1585 (m); 1560 (m)
• 1470–1450 (s)
• 1400 (s); 1430 (m)
• 1375 (m)
• 1340 (m); 1215 (m)
• 1135 (s)
• 1060 (m); 1030 (m); 1015 (m)
• 955 (m); 930 (m); 920 (m)
• 825 (s); 800 (s)
• 790 (s); 760 (s)
• 710 (m); 700 (s); 670 (s)

Claim structure matters:

• The claim includes band locations and intensity labels (w/m/s). While intensity is sometimes treated as evidentiary rather than limiting, the claim text expressly characterizes intensity, which strengthens the metrology constraint.
• It limits to FTIR in KBr, not ATR, not neat sample, not other solvents.

How do dependent claims 4–7 expand protection: single-crystal XRD parameters and atomic positions?

Claims 4–7 are the structural “lock” that goes beyond spectral fingerprints.

What single-crystal XRD features are required (Claims 4/5/6/7)?

The dependent claims require a polymorph that exhibits a single-crystal X-ray analysis with:

• Orthorhombic space group: P2₁2₁2₁
• Unit cell approximately:
  • a = 8.004(5) Å
  • b = 8.372(5) Å
  • c = 25.21(2) Å
  • α = 90.00°, β = 90.00°, γ = 90.00°
  • V = 1689.3(6) ų
• Crystal size: 0.11 × 0.11 × 0.12 mm
• Molecules/unit cell: 4
• Density: 1.354 g/cm³
• And critically: atomic positions relative to the origin as recited in Tables 3 and 7, and represented in FIG. 3.

Scope effect: higher certainty but narrower infringement surface

Because single-crystal parameters and atomic coordinates are far less likely to be replicated accidentally, these dependent claims typically:

• Narrow the claim set relative to XRPD/FTIR-only definitions.
• Provide a strong basis for enforcement where defendants have crystallographic data matching the claimed structure.

Which pharmaceutical compositions are covered: what dosage forms and carriers does Claim 8–11 cover?

Claims 8–11 are composition claims that wrap the polymorph into a general pharmaceutical composition concept.

What do Claims 8–11 require?

Each composition claim requires:

• An amount of the polymorph of a referenced claim (Claim 1 for Claim 8; Claim 2 for Claim 9; Claim 4 for Claim 10; Claim 7 for Claim 11),
• effective in treating specified conditions,
• plus a pharmaceutically acceptable carrier.

The claims are not limited to a particular dosage form in the text you provided (no tablets/capsules/injectables limitation shown). As written, they would cover typical conventional formulation formats that use acceptable carriers, so long as the solid-state polymorph requirement is met.

Indication sweep in composition claims

Claims 8–11 recite multiple condition categories:

• depression
• anxiety-related disorders
• obesity
• chemical dependencies or addictions
• premature ejaculation

What therapeutic methods are covered: administration methods and indication list (Claims 12–15)?

Claims 12–15 are method-of-treatment claims.

What do the method claims require?

Each requires:

• treating a condition selected from the same list as the composition claims,
• administering to a human an amount of the polymorph of the referenced claim (Claim 1, 2, 4, or 7 respectively),
• effective for treating such condition.

Scope: single administration paradigm, multi-indication coverage

As drafted, the method claims do not enumerate dose mg, dosing frequency, titration, treatment duration, or patient subsets in the excerpted claim text. That omission generally broadens method coverage to “an amount effective,” constrained by functional efficacy.

How broad is the overall patent estate by claim dependency depth?

A clean way to map the claim hierarchy:

Net effect: the claims build from solid-state identity (1/2/4/7) into composition and method use. Enforcement hinges on whether the accused product is the claimed hydrochloride polymorph and whether it is used to treat one of the recited condition categories.

How could competitors design around: what are the legal/IP “escape hatches” from this claim set?

Because the claims are so metrology-defined, design-around usually targets one or more gates:

1) Change the salt form

Claim text fixes the solid-state identity as a hydrochloride salt. A different counterion salt (e.g., sulfate, mesylate) is outside the polymorph definition as written.

2) Use a different stereochemical form

The API is restricted to (1S-cis). Racemates or other stereoisomers that do not meet (1S-cis) fall outside.

3) Use a different polymorph that fails the XRPD/FTIR gates

If an alternative polymorph produces:

• different XRPD peak positions beyond tolerance, or
• different FTIR KBr band positions/intensities, then Claims 1/2 (and dependent chains that rely on them) should not read.

4) Avoid single-crystal matching (if asserting dependent claims)

Claims 4–7 require the specific crystallographic parameter set and atomic positions. Even if XRPD and FTIR approximate can be argued, dependent claims typically remain harder to satisfy.

5) Avoid the recited therapeutic indications

The method and composition claims require treatment/effectiveness for specific condition categories. A product labeled and used only for unclaimed indications would reduce method-of-use infringement risk, though composition claims tied to an “effective in treating” functional language can complicate that.

What is missing for Orange Book / FDA exclusivity / litigation landscape mapping?

No FDA brand/generic mapping, Orange Book listing details, or assignee/public litigation record is included in the provided input. Without those, a reliable analysis of:

• Orange Book status,
• FDA approval pathways,
• Paragraph IV challenges,
• settlement structures,
• current market authorization, cannot be produced from the claim text alone.

Key Takeaways

• US 5,248,699 is built around a specific hydrochloride polymorph of a fully specified (1S-cis) tetrahydro-N-methyl-naphthylamine.
• Claim 1 enforces a specific XRPD peak set; Claim 2 enforces a specific FTIR (KBr) band set.
• Claims 4–7 add an even stronger structural requirement through single-crystal XRD (space group P2₁2₁2₁; unit cell parameters; atomic positions in Tables 3 and 7; FIG. 3).
• Composition and method claims (8–15) are broad in therapeutic scope, covering depression, anxiety-related disorders, obesity, chemical dependencies/addictions, and premature ejaculation, but they still require the claimed polymorph.

FAQs

1. Does Claim 1 cover any hydrochloride polymorph with similar XRPD peaks, or only the exact peak positions?
   The claim requires an XRPD pattern with characteristic peaks at the listed approximate 2θ values, so infringement depends on whether the accused form meets that metrology threshold.

2. Can a defendant avoid Claim 2 by switching from KBr pellet FTIR to ATR-FTIR?
   Claim 2 specifies FTIR in potassium bromide (KBr), which constrains the testing condition used in the claim.

3. Are dependent claims 4–7 automatically broader than Claims 1–3?
   No. They add single-crystal crystallographic parameters and atomic positions, narrowing the set of structures that satisfy the claim.

4. Do the method claims require specific dosing regimens?
   The excerpted language uses “an amount effective,” with no explicit mg/day schedule in the provided claim text.

5. Do composition claims 8–11 implicitly require all the listed indications simultaneously?
   No. The claims state “effective in treating” the conditions listed; infringement analysis typically turns on the intended/actual therapeutic use against one of the enumerated categories.

References

1. United States Patent 5,248,699 (provided claim text).